Background: Optimal haemostasis management in orthotropic liver transplant (OLT) could reduce blood loss and transfusion volume, improve patient outcomes and reduce cost. Methods: We performed a study including 336 OLTs to evaluate the clinical and cost effectiveness of a new pointof-care (POC)-based haemostatic management approach in OLT patients. Results: In terms of health benefit we found that the new approach showed a significant reduction in transfusion requirements (red blood cell transfusion units were reduced from 5.3 ± 4.6 to 2.8 ± 2.9 [p < 0.001], free frozen plasma from 3.1 ± 3.3 to 0.4 ± 1.0 [p < 0.001] and platelets from 2.9 ± 3.9 to 0.4 ± 0.9 [p < 0.001], transfusion avoidance, 9.7% vs. 29.1% [p < 0.001] and massive transfusion, 14.5% vs. 3.8% [p = 0.001]); we also found a significant improvement in patient outcomes, such, reoperation for bleeding or acute-kidney-failure (8.3% vs. 2.4%, p = 0.015; 33.6% vs. 5.4%, p < 0.001), with a significant reduction in the length of the hospital total stay (40.6 ± 13.8 days vs. 38.2 ± 14.4 days, p = 0.001). The lowest cost incurred was observed with the new approach (€73,038.80 vs. €158,912.90) with significant patient saving associated to transfusion avoidance (€1278.36), ICU-stay (€3037.26),
Introduction
Orthotopic liver transplantation (OLT) has become the first-line approach for the treatment of patients with endstage liver disease [1, 2] . Historically, OLT has been associated with major blood loss, the need for massive blood product transfusion, poor patient outcomes and significant associated expenses [3, 4] .
Despite of the progress achieved during the last years, from graft preservation through to surgical techniques and anaesthetic management, determining the optimal haemostasis management approach remains one of the greatest challenges in OLT [5, 6] . So marked variations in inter-institutional transfusion requirements for OLT still persist [7] . In addition, substantial evidence suggests that the use of blood products during OLT is associated with a high number of post-operative adverse events and may negatively affect the evolution of the procedure, resulting in limited patient outcomes [8, 9] and leading to increased associated costs.
Point-of-care tests (POCTs) may overcome some of the limitations of the traditional approaches to haemostasis management [10, 11] based on conventional coagulation tests such as prothrombin-time and the international normalised ratio (INR) conducted at the main laboratory. These tests are neither good predictors of bleeding nor do they provide sufficient information to optimise the management of bleeding event in patients with liver disease who undergo invasive or surgical procedures such as OLT [12, 13] . Commercially available whole blood viscoelastic tests (thromboelastography [TEG] and thromboelastometry [ROTEM] ) in association with other available POCTs such as, blood-cell count, metabolic tests or blood gas, would allow assessing disruptive haemostasis monitoring strategies sensitive to all major pathomechanisms involves in the coagulation defects during the OLT at the patient site [14] .
The objective of this study was to evaluate from the perspective of the Spanish Health Service, the clinical and cost effectiveness of a new approach based in POC testing to guide the diagnosis, management and monitoring of haemostasis disorders during OLT. Our first aim was to evaluate the clinical effectiveness in terms of reduction of transfusion requirements, reoperation rates and the occurrence of immediate postoperative complications. The second aim was to evaluate the economic impact of our new approach in term of cost-effectiveness analysis.
Materials and methods

Study design
We conducted a comparative analysis to evaluate clinical and cost effectiveness of the use of a new POC-based approached for haemostasis management in OLT. A cohort of 336 patients undergoing OLT performed at the Virgen del Rocio University Hospital in Seville (Spain) was included. Analysis was conducted from 2013 to 2017 under the perspective of the Spanish healthcare system. Informed consent was obtained for all patients. The study protocol was approved by the Ethic Committee from Virgen del Rocio University Hospital (PI/158).
Comparative analysis was conducted on two separate patient groups: The "standard-care group" (SCG) included 168 consecutive patients whose haemostasis and transfusion management was assessed supported by routine laboratory testing performed at the main laboratory. The transfusion management of unusual complications was decided according to preestablished guidelines. Red blood cells (RBCs) were transfused to maintain the haemoglobin (Hb) level higher than 7 g/dL. Transfusion of non-RBC blood products was based on clinical grounds and guided by the results of the standard coagulation tests according to specific protocol. The thresholds for selecting free frozen plasma (FFP), and platelets (PLTs) were INR of greater than 1.6, plasma fibrinogen level of less than 1.0 g/L, and PLT count of less than 70 × 10 9 /L, respectively. Ionised calcium (iCa) levels maintained >1 mmol/L and pH > 7.2 with 8.4% sodium bicarbonate. The Cobas ® 6000 modular analyser (Roche Diagnostic, Mannheim, Germany) was used to measure glucose, sodium, potassium and creatinine serum levels; pH and iCa were analysed in a ABL800-FLEX ® blood gas analyser (Radiometer Medical A/S, Bronshoj, Denmark); haemogram was recorded using an XE-2100 counter (Sysmex, Mundelein, IL, USA); plasma coagulation tests: INR, aPTT and fibrinogen, were performed on an ACL-TOP-500 ® (Instrumentation Laboratory, Bedford, MA, USA). The "POC group" (POCG) included 168 consecutive patients whose haemostasis and transfusion management was decided according to a specific algorithm based in a mobile laboratory unit (MLU) results placed into the operation room [14] . The idea of this new approach is to provide immediate rapid diagnosis of coagulation disturbances and guide goal-directed haemostatic therapy at the patient's bedside. The MLU includes: a Cobas ® b 221 (Roche Diagnostic, Mannheim, Germany) to perform blood gas analyses and record pH, glucose, sodium, potassium, iCa and lactate levels; a pocH-100i cell counter (Sysmex, Mundelein, IL, USA) and a Thromboelastometry device (ROTEM, TEM International GmbH, Munich, Germany) for real-time haemostasis monitoring. Blood samples were tested immediately after collection in the operation room.
Cost-effectiveness analysis
To evaluate the cost effectiveness, we adapted the model structure used by the Health Technology Assessment (HTA) undertaken for NHS Scotland in 2008, which was largely based on a cost-effectiveness study of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion by Davies et al. [15] . The model started with the diagnostic test/transfusion management strategy to follow, which can use an SC or a POC approach. During the OLT procedure, the patient may need a transfusion or not, with the probabilities of requiring transfusions varying across strategies. Patients requiring transfusion may experience complications. Only events for which data were available and that were considered to be serious events associated with blood transfusion were included in the model. The time horizon was limited to 1 month to capture the impact of complications and mortality occurring during the period of hospitalisation. A time horizon of 1 year was considered in transfusion-related mortality analyses so that at least some of the long-term effects of could be included in the analysis.
Clinical effectiveness
The clinical effectiveness was assessed according to the transfusion events, the complication usually related to it and the mortality rate in both groups. Transfusion events were considered in terms of transfusion rates (RBC, FFT and PLTs transfused), total avoidance of transfusion, the frequency of intraoperative massive transfusion (MT) defined as: when either (1) total blood volume is replaced within 24 h, (2) 50% of total blood volume is replaced within 3 h, or (3) rapid bleeding rate is observed that in adults can be defined as more than 4 units of RBCs transfused within 4 h with active major bleeding or more than 150 mL/min of blood loss. The effectiveness model also included the complications that usually are linked with bleeding such as reoperation to investigate bleeding, the presence of acute kidney injury (AKI) and early mortality (30 days) and 1-year survival rates. The health benefit of using POC testing was estimated in terms of the numbers of quality-adjusted life years (QALYs) gained in 1 year, calculated from the cohort survival data using a utility value of 0.93 for the patients that did not receive a transfusion and 0.88 for the patients that received transfusion. These utility data express the impact of transfusion and their complications in the life quality of the patients, and were obtained from a report of the National Health Service/Quality Improvement Scotland [16] .
Cost analysis
The cost analysis was conducted from the perspective of the Spanish health services, according to that, the follow categories of costs were included in the study ( Table 1 ). The cost of the laboratory test conducted according with the different haemostasis approaches; we considered an average of three testing during the procedure with total cost for the procedure of €26.31 for the SCG (blood cell counter, routine coagulation testing and blood gas analysis) and €130.95 for the POCG (POC-blood cell counter, POC-thromboelastometry and POC-blood gas analysis). The cost of blood product transfusion; we included the three types of blood components RBC (€142.98/unit transfused), FFP (€63.19/unit transfused) and PLTs (€300.12/unit transfused). The hospitalisation cost; the estimation of the cost related with the hospitalisation time was estimated assuming the total cost of the diagnostic related groups (DRGs) for a liver transplant of €74,091.61 and the length of the stay of 29.9 days. The cost of the stay was adjusted for each patient according with their length of the stay and considering the cost for 1 day of €2535.69. No indirect costs were included in the study. The cost associated with the reoperation to investigate bleeding; the estimation of the cost was calculated according with the cost for the specific DGR of €13,711.80. All costs were adjusted by inflation to reflect cost related to the year 2017.
Statistical analyses
A descriptive analysis was carried out using qualitative variables, represented in the tables as absolute frequencies and percentages. Quantitative variables were expressed using mean and standard deviation (SD) . Differences between groups were tested using the Mann-Whitney U-test, the Pearson's χ 2 -test or Fisher's exact test, as appropriate. All statistical analyses were conducted using software with the Statistical Packed for the Social Sciences (SPSS version 20.0, Chicago, IL, USA).
Cost-effectiveness analysis:
The methodology includes an incremental cost-effectiveness analysis, the results are reported as the incremental cost per additional unit of benefit obtained. After determining the preferred strategy, we compared the overall budget impact of using that strategy within the Spanish Health Service. This estimation was weighed by the number of OTL performed in Spain in 1 year (we use as a reference the number of OLT performed in the year 2016, using the data base from the Spanish National Transplant organization [www. ont.com]). To assess the impact on the budget we simulated three different scenarios: The best-case scenario involved that 100% of the OLTs performed in 1 year were conducted using the new approach, the intermediate-case scenario involved that 75% of the OLTs were conducted using the new approach and the worst-case scenario where only 50% of the OLTs were conducted using the new approach. Finally, to assess the influence of parameter uncertainty in the results of the analysis and to evaluate their robustness, a probabilistic sensitivity analysis was carried out using a second-order Monte-Carlo technique in a hypothetical cohort of 1000 patients. Simulating the basic results of the model shows the probability that these remain stable during simultaneous variations in the main parameters. This internal validation of the results is achieved by imputing a gamma distribution for unit cost, log-normal distribution for use of resources and a beta distribution of effectiveness parameters following international recommendations [17] .
Results
Health benefits
Transfusion requirements differed significantly between the two groups ( Table 2 ). The media of intraoperative allogenic RBC unit transfused/patient was 5.3 ± 4.6 in the SCG and 2.8 ± 2.9 in the POCG (p < 0.001). FFP transfusion was 0.4 ± 1.0 in the POCG compared with a media 3.1 ± 3.3 units per patient in the SCG (p < 0.001). The media of the PLTs unit transfused was 2.9 ± 3.9 in the SCG and 0.4 ± 0.9 in the POCG (p < 0.001). In addition, total avoidance of transfusion was greater in the POCG, with 29.1% of patients completely avoiding allogeneic blood transfusion compared with only 9.7% in the SCG (p < 0.001). Intraoperative MT was more common in the SCG (14.5% of patients vs. 3.8%, p = 0.001). Table 2 also summarises the immediate postoperative complications. There were differences in the rates of complications, with a significant reduction in the POCG for re-operation due to bleeding (p = 0.015), postoperative surgical haemorrhage (p = 0.044) and AKI (p ≤ 0.001). We also found significant differences in the length of the ICU stay 8.4 ± 7.5 days in the POCG and 10.2 ± 7.6 days in the SCG (p = 0.031). The total stay was 40.9 ± 13.8 days for SCG and 38.2 ± 14.4 days for the POCG (p = 0.001).
The results of early mortality when we considered a time horizon of 1 month showed a minimal difference between the SCG and the POCG. Also, when we considered the 1-year survival rate, the differences between both groups are not statistically significant. Table 3 shows the incremental cost for both strategies. The lowest cost incurred was observed in those patients managed with the POC approach. We found significant cost reduction to the POCG in transfusion associated cost (€1278.36), ICU stay associated cost (€3037.26), total stay associated cost (€3800.76) and the reoperation by bleeding associated cost (€80,899.64). The total cost for patient in the POCG was €73,038.80 while the cost for patients in the SCG was €158,912.90. The incremental cost of the SC-approach was €85,874.10 for patient in relation with the POC approach. The results of the incremental costeffectiveness analysis showed that the POC approach was the dominant strategy for the haemostasis monitoring of patient under OLT as it achieved better health outcomes and lower cost when we compared with the SC strategies. Table 4 summarises the results of the budget impact of using that strategy within Spanish Health Service. When the savings per patient were translated to the overall patient population undergoing liver transplantation, the total potential saving achieved with the use of that new approach were 10,054.325€ in the best scenario (100% of the OLTs performed in 1 year conducted using the POC approach), 7540.744€ in the medium scenario (75% of the OLTs performed in 1 year conducted using the POC approach) and 5027.163€ in the worst case scenario (50% of the OLTs performed in 1 year conducted using the POC approach). Figure 1 shows the results of the sensitivity analysis conducted on the model. The analysis showed that the POC approach became the dominant strategy compared with the strategy based on the SC procedure. The POC approach is the dominant strategy in 58% of the simulated cases with an incremental cost saving of €12,000. In relation with QALYs gained and cost for QALYs of the POC approach showed that more than 76% of the simulated cases were cost-effective (cost for QALYs gained less than €30,000) or dominant.
Cost analysis
Budget impact
Sensitivity analysis
Discussion
In this study, we evaluated the clinical-and cost-effectiveness of a new approach based on POC testing to assist the diagnosis, management and monitoring of haemostasis disorders during OLTs. We found that the POC strategy was associated with a significant reduction in the transfusion Figure 1 : Results of the sensitivity analysis conducted on the model. The POC approach showed that more than 76% of the simulated cases were cost-effective (cost for QALY gained less of €30,000). QALYs; Quality adjusted life year. Preference-based measure of health outcome that combines length of life and health related quality of life (utility scores) in a single metric.
requirement, compared with the SC procedure based on routine testing performed in the main laboratory. In addition, we found that more patients avoided blood product transfusion and MT and also displayed improved clinical outcomes and ICU stay. The results of the cost-effectiveness showed that the POC approach was the dominant strategy of patients undergoing OLT as it achieved better health outcomes and lowest costs compared with the SC procedure.
The benefits of using POC haemostatic monitoring during liver surgery have previously been disputed [18] , however, they are increasingly used in this setting and are now recognised as being useful [19] . There is increasing evidence that using POCTs as part of a haemostasis management strategy is associated with reduced blood product usage in OLT patients [20] . Our results confirm that finding, we show that our strategy based on POC monitoring is more effective in reducing transfusion requirements of blood products and has the potential to greatly reduce the rate of MT and improve the necessity for transfusion. Compared with other OLT studies, we observed a greater decrease in the requirements for blood product transfusion, particularly FFP and PLTs [21, 22] and transfusion is avoided. Our results are similar to Massicotte et al. [23] , who to the best of our best knowledge, reported the lowest rates of transfusion in this setting. In a previous study, our group demonstrated the strong association between the haemostasis management and transfusion event, so in our opinion, POC haemostasis monitoring during OLT significantly reduces the transfusion requirements [24] .
Intraoperative hypovolemia and significant blood loss usually require massive amounts of intravenous fluid and blood products to preserve cardiac output and organ perfusion. However, massive blood transfusion with fluid administration is not free from complications in the postoperative period. The Health Technology Assessment report [15] concluded that, the use of POC devices appeared to be clinically effective, reducing the need for inappropriate transfusions, decreasing blood component requirements and reducing the number of complications. The results of our study are consistent with this previous report in that they suggest that the use of POC devices may be a clinically effective approach to the management of haemostasis in patients undergoing liver transplant. We found a significant reduction in the immediate complications associated with OLT such as the rate of re-exploration due to bleeding which was lower in more than 50% for patients treated using the POC approach, only 5% of the patient using the POC needed reexploration. Hendriks et al. [25] previously reported that 24% of patients underwent surgical re-intervention due to bleeding during the initial hospitalisation period. Intraoperative haemodynamic disturbances and massive transfusion may also lead renal dysfunction, another important concern in OLT. The true incidence of renal failure is not known, it has been reported to vary from 5% to 50%. Ojo et al. [26] reported a strong association between renal failure and an elevated risk of death after transplantation. In our study patients under POC monitoring had a significant reduction in incidences of AKI, only 5.4% of the patients under POC monitoring developed AKI, probably associated with better haemostasis management, faster haemodynamic stabilisation and better kidney function preservation. There was some evidence of reduced ICUstay in the POCG compared with the SCG, but this was not consistently reported across studies. Our results show that the patient under the POC approach reduced their stay in the hospital, we found a significant difference between groups principally in the ICU stay probably associated a better haemostasis management and less immediate post-operative complications.
As regards mortality when we considered a time horizon of 1 month and 1 year we did not show significant differences between both groups. Our survival rates results, 92.8% at 30 days and 85.7% at 1 year, are similar to those published by other groups and pretty similar to the rate described in the main registers from the European [27] and the American Liver Transplant data base [28] . Our result are in agreement with a previous Cochrane review [29] , last updated in 2011, which evaluated the effectiveness of transfusion strategies guided by POC devices in patients with severe bleeding. This review concluded that there was no evidence that POC monitoring improved mortality. In our opinion the lack of evidence in improving rates of survival is related with the fact that mortality in OLTs is a multifactor problem associated with the characteristics of the patients and the procedure itself. In agreement with that, Bilbao et al., reported that early mortality in liver transplant is associated with the basal clinical condition of the recipient, the functional success of the graft, the surgical complications encountered and the immunosuppressive therapy [30] .
The cost-effectiveness analysis suggested that the POC approach is cost-saving and more effective than standard laboratory monitoring in OLTs. The per-patient cost-saving was €85,874.10. When the cost per patient according to the type of cost category are compared, we observed a incremental cost of €104.64 for testing in the POCG due to the viscoelastic test being included in that approach which is more expensive than the conventional coagulation test, but the cost category showing the most impact in the overall cost/ saving per patient was the cost of the hospitalisation which would be €3,037.26 lower in an ICU stay; and €763.48 lower in a ward stay, followed by the cost related with a transfusion with a saving of €1278 per patient. Our results are consistent with previous studies, Craig et al. [15] , reported an incremental cost of £80 when they compared the viscoelastic test and the conventional coagulation test in OLT haemostasis monitoring. They also found the highest impact in the saving per patient was the cost of hospitalisation £4412 per patient and the cost in blood product transfused £2272 per patient. These results are confirmed by the probabilistic sensitivity analysis showing an average saving of €12,000 and the POC option is the best in 58% of simulates cases. Scenario analyses were used to assess the potential impact of changing various input values for the model. In these scenarios the results remained largely unchanged when all of the uncertainties included in the model were taken into account, at a cost-effectiveness threshold of €30,000 per QALY, the probability of cost-effectiveness for the POCapproach was 0.76.
Our results have important policy implications and may be more broadly applicable to our health care system, which assume both the costs and benefits of treatment. In practice, resource constraints limit treatment capabilities. Our analyses suggest that such efforts to improve treatment capacity in the short term could ultimately lead to substantial longterm improvements in health outcomes and reduced costs for patients undergoing OLT. Our scenario analysis shows that the benefices of using our POC approach in normal practice in Spain with estimated savings, in the best-case scenario, of about 10 million Euros per year. Although we demonstrate that treating any patient is cost-effective compared to the current strategies, practical limitations influence the clinical application of these findings but in our opinion these results encourage the idea that it may be the time to change the coagulation management in OLTs.
There are some limitations to our study. It was not a prospective randomised trial, we used a non-probabilistic consecutive sampling to select the patients included in the study. In our opinion, in this case we believe that it would be unethical to have used a randomised design because the large body of evidence that supports the use of POC testing for haemostasis and transfusion management in major surgeries such as liver transplant. On the other hand, the large sample size used combined with the type of variables analysed in our study might overcome the limitations when using a non-probabilistic sampling method. Another limitation is that our study only reflects the experience of a single hospital. Our analyses were conducted from the Spanish health system perspective, including Spanish specific pricing. To improve the generalisability of our results, we included general population data in ranges used for sensitivity analyses. We also demonstrated the prices and efficacy necessary for cost-effectiveness at each cost-effectiveness threshold, making our results relevant to systems with other pricing structures.
In conclusion, we determined that POC-based haemostasis management is economically and clinical effective in patients undergoing OLT. Our results indicate that the use of POC testing is associated with a reduction in the transfusion rates and improvement in clinical outcomes. The cost-effectiveness analysis indicated that the POC strategy is cost-saving and more effective than current practice. Our scenario used to assess the potential impact did not alter this conclusion.
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